Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659312 | 0.93 | ECE1 (0.38) | ECE1MMP2MMP3CYP1A2CYP3A4 | |
| SCHEMBL2656898 | 0.93 | ECE1 (0.38) | ECE1CNR1MMP2MMP3FFAR2 | |
| SCHEMBL2656112 | 0.88 | KMT2A (0.41) | MEN1KMT2ACNR1FPR2CYP1A2 | |
| SCHEMBL2656108 | 0.82 | FFAR2 (0.38) | MEN1KMT2ACNR1FPR2FFAR2 | |
| SCHEMBL2658750 | 0.81 | KEAP1 (0.37) | MEN1KMT2ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2656110 | 0.81 | ACACB (0.37) | MEN1KMT2ACNR1FFAR2LTB4R2 | |
| SCHEMBL2643975 | 0.80 | GCGR (0.39) | MEN1KMT2ACNR1FPR2LTB4R2 | |
| SCHEMBL2644086 | 0.80 | GCGR (0.39) | MEN1KMT2ACNR1FPR2LTB4R2 | |
| SCHEMBL2643070 | 0.80 | GCGR (0.40) | FPR2FFAR2 | |
| SCHEMBL2644303 | 0.80 | GCGR (0.39) | MEN1KMT2ACNR1FPR2LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ECE1 1089/4885MEN1 2605/4885KMT2A 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.